Who is sponsoring NCT00006089?

NCT00006089 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00006089?

Interventions in NCT00006089: Laboratory Biomarker Analysis, Trastuzumab.

What condition does NCT00006089 study?

NCT00006089 studies Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7.

Is NCT00006089 still recruiting?

NCT00006089 is currently completed. Last updated 31 July 2019.

Last reviewed 2019-07-31 · How we verify

NCT00006089

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Completed Phase 2 Last updated 31 July 2019

What this trial tests

Phase 2 trial testing Laboratory Biomarker Analysis in Endometrial Adenocarcinoma in 34 participants. Completed in 31 January 2010.

Timeline

18 September 2000

Primary endpoint
4 September 2007

31 January 2010

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	18 September 2000
Primary completion	4 September 2007
Estimated completion	31 January 2010
Sites	1 location across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Trastuzumab (trastuzumab) — full drug profile →

Conditions studied

Endometrial Adenocarcinoma — all drugs for Endometrial Adenocarcinoma →
ERBB2 Gene Amplification — all drugs for ERBB2 Gene Amplification →
Recurrent Uterine Corpus Carcinoma — all drugs for Recurrent Uterine Corpus Carcinoma →
Stage III Uterine Corpus Cancer AJCC v7 — all drugs for Stage III Uterine Corpus Cancer AJCC v7 →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, female only, with Endometrial Adenocarcinoma or ERBB2 Gene Amplification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage III, stage IV, or recurrent endometrial cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
Halle MK, Tangen IL, Berg HF, Hoivik EA, et al · · 2018 · cited 58× · PMID 29169184 · DOI 10.1038/bjc.2017.422
Pathogenesis and Clinical Management of Uterine Serous Carcinoma.
Zhang L, Kwan SY, Wong KK, Solaman PT, et al · · 2020 · cited 21× · PMID 32183290 · DOI 10.3390/cancers12030686
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y, Erfani S, Schweer D, de Gouvea R, et al · · 2023 · cited 15× · PMID 36911068 · DOI 10.1016/j.omto.2023.02.006
Genomics of uterine malignancies and the potential of precision medicine.
Polidano J, Jarratt A, Scott CL, Barker HE. · · 2025 · PMID 41306899 · DOI 10.1177/17588359251387395

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other recruiting trials for Endometrial Adenocarcinoma

Currently open trials in the same condition.

NCT07077876 — Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Tre · recruiting
NCT06917092 — QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT05824481 — Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer · Phase 2 · active not recruiting
NCT05548296 — A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · Phase 2 · recruiting
NCT05112601 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · Phase 2 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00006089 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 31 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00006089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing